Prolyl hydroxylase inhibitors
AssigneeGlaxoSmithKline LLC
InventorsDuke M. Fitch, Antony N. Shaw, Kenneth Wiggall
Life of this patent
Estimating the term…
Abstract
The invention described herein relates to certain pyrimidinetrione N-substituted glycine derivatives of formula (I) which are antagonists of HIF prolyl hydroxylases and are useful for treating diseases benefiting from the inhibition of this enzyme, anemia being one example.
Claims2
A method of treating anemia associated with renal disease in a human comprising administering to such patient N-[(1,3-dicyclohexyl-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl)carbonyl]glycine.
A method of treating anemia associated with renal disease in a human comprising administering to such patient N-[(1,3-dicyclohexyl-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl)carbonyl]glycine, or a pharmaceutically acceptable salt thereof.
Dependencies are inferred from the claim text.